NCT00272961

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.

Detailed description

The study was stopped due to Pfizer (sponsor) decision that the compound would not be involved in any further clinical development for the indication of resistant hypertension on 05 August 2008. This decision was not based on any safety or efficacy concern.

Conditions

• Resistant Hypertension

Interventions

Type	Name	Description
DRUG	Placebo	placebo tablet once daily for 12 weeks
DRUG	TBC3711	10 mg tablets once daily for 10 weeks
DRUG	TBC3711	50 mg tablet once daily for 10 weeks
DRUG	TBC3711	100 mg tablet once daily for 10 weeks
DRUG	TBC3711	200 mg tablet once daily for 10 weeks

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2006-01-09
• Last updated: 2013-03-05
• Results posted: 2013-03-05

Locations

12 sites across 1 country: United States